Comparative Improvement of RBC Indices and Hemoglobin After Oral Versus Iron Therapy in Patients of Iron Deficiency Anemia
DOI:
https://doi.org/10.21276/apalm.2057Keywords:
Iron Deficiency Anemia, IVIS, OI, Serum ferritin, HemoglobinAbstract
Background: Iron Deficiency Anemia (IDA) is the single most prevalent nutritional deficiency worldwide. Oral iron therapy is the standard of care, however in some cases parenteral iron therapy is required. This study was undertaken to evaluate the comparative improvement of RBC indices and hemoglobin after treatment with IV Iron sucrose complex and oral iron in iron deficient patients.
Methods: A retrospective study was conducted at Super Speciality Hospital in North India on 50 patients in Department of Pathology and Clinical Hematology who were diagnosed with IDA/state based on complete blood counts (CBC), iron studies and ferritin levels. Patients on chronic proton pump inhibitor therapy or celiac disease were treated with IV iron sucrose complex (IVIS) 100 mg for 10 days and remaining were given oral iron (OI), i.e. Ferrous sulfate 100 mg 2-3 times a day. All patients were given folic acid 5 mg daily in addition to iron therapy. Various hematological parameters were compared at day 12-15 days of therapy. Statistical analysis was done by student t test. Values were considered statistically significant when p<0.05.
Result: - A total of 50 patients were included, out of which 10 received IVIS and 40 were treated with oral iron therapy. Patient belonged to age group 15-45 years. Although hemoglobin increased in both groups; rise in reticulocyte count, MCV, MCH, MCHC and increase in hemoglobin were higher in IVIS than in OI group at day 12-15 of therapy (25.7% vs 10.8%). IVIS has no major side effects. Compliance was not very good with OI group; 20% patients showed GI side effects and 5 patients left therapy because of the same.
References
2. World Health Organization. Reduction of maternal mortality. A joint WHO/UNFPA/UNICEF/World bank statement. Geneva: WHO; 1999.
3. Breymann C, Gliga F, Bejenariu C, Strizhova N. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. International Journal of Gynaecology & Obstetrics. 2008; 101:67-73.
4. Schrier SL. Treatment of anemia due to iron deficiency.Uptodate.com.2010; 3/19.
5. Breymann C. Treatment of iron deficiency anemia in pregnancy and postpartum with special focus on intravenous iron sucrose complex. Journal of the Medical Association of Thailand. 2005;88: S108-9.
6. Tan AE, and Siti SA. Intravenous iron-sucrose complex for treatment of Iron Deficiency Anemia in Pregnancy - experience in an Obstetric Day Care Clinic in a Tertiary Hospital. Medicine & Health, 2008; 3 (2): 288-293.
7. Bayoumeu F, Subiran-Buisset C, Baka NE, Legagneur H, Monnier-Barbarino P, Laxenaire MC. Iron therapy in iron deficiency anemia in pregnancy: Intravenous route versus oral route. Am J Obstet Gynecol. 2002; 186:518–22.
8. Silverstein SB, Rodgers GM. Parenteral iron therapy options. Am J Hematol. 2004; 76:74
9. Perewusnyk G, Huch R, Huch A, Breymann C. Parenteral iron therapy in obstetrics: 8 years’ experience with iron-sucrose complex. Br J Nutr. 2002; 88:3-10.
10. Abdullah et al. Intravenous iron sucrose vs oral iron therapy in treatment of pregnancy with moderate anemia:A prospective sudy in a tertiary care centre. International Journal of Basic and Applied Medical Sciences.2014; Vol.4(2):78-83
11. Kumar A, Jain S, Singh NP, Singh T. Oral versus high dose parenteral iron supplementation in pregnancy. Int J Gynaecol Obstet. 2005; 89:7–13.
12. Syal N, Nair NS, Rai L. Iron Sucrose Versus Oral Iron Therapy in Pregnancy Anemia.Indian J Community Medicine.2012; Oct-Dec 37(4):214-218
13. Al-Momen AK, Al-Meshari A, Al-Nuaim L, Saddique A, Abotalib Z, Khashogji T et al. Intravenous iron sucrose complex in the treatment of iron deficiency anemia during pregnancy. Eur J Obstet Gynecol Reprod Biol. 1996; 69:121–4.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 Mona Bargotya, Payel Das, Lalit Kumar, Mukul Aggarwal
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).
